Press release
Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co.
Explore our latest breakthroughs in Esophageal Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Esophageal Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
* June 2024:- Sichuan Baili Pharmaceuticals- Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma. This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.
* DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
* The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
Stay informed about the cutting-edge advancements in Esophageal Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
* Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene's immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.
* Serplulimab: Shanghai Henlius Biotech
Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).
Learn more about Esophageal Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Esophageal Squamous Cell Carcinoma Research and development projects @ Esophageal Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Squamous Cell Carcinoma Companies
BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Discover the latest advancements in Esophageal Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
* Coverage- Global
* Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Esophageal Squamous Cell Carcinoma Pipeline on our website @ Esophageal Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Esophageal Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Squamous Cell Carcinoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tislelizumab: BeiGene
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RAPA-201: Rapa Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* SGN-B6A: Seagen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Esophageal Squamous Cell Carcinoma Key Companies
* Esophageal Squamous Cell Carcinoma Key Products
* Esophageal Squamous Cell Carcinoma- Unmet Needs
* Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
* Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Esophageal Squamous Cell Carcinoma Analyst Views
* Esophageal Squamous Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-squamous-cell-carcinoma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-beigene-shanghai-henlius-biotech-cstone-pharmaceuticals-jiangsu-hengrui-medicine-co]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co. here
News-ID: 3564795 • Views: …
More Releases from ABNewswire
Kitchen Remodeling Enhances Both Functionality and Aesthetics in Homes
Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier.
Kitchen remodeling [https://neadesignandconstruction.com/#:~:text=01,Kitchen%20Remodeling] continues to shape the way homes are experienced across New Jersey, as families prioritize comfort, efficiency, and long-lasting design. Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier. With demand rising for reliable services, homeowners are turning to trusted providers like…
Home Remodeling Trends Position New Jersey as a Hub for Modern Design
Blending traditional craftsmanship with modern innovation, NEA Design and Construction continues to highlight how the state is becoming a leader in functional and stylish design transformations.
The demand for Home remodeling [https://neadesignandconstruction.com/#:~:text=Elevate%20Your-,Home,-Proudly%20serving%20homes] has seen remarkable growth in recent years, with many New Jersey property owners choosing to update and modernize their living spaces. Blending traditional craftsmanship with modern innovation, NEA Design and Construction continues to highlight how the state is becoming…
Local Infrastructure Strengthened Through General Contractor Expertise of NEA De …
Whether involving renovations, new builds, or large-scale developments, property owners require professionals who bring both expertise and reliability.
The demand for skilled general contractor [https://neadesignandconstruction.com/#:~:text=experience%20in%20the-,construction,-industry%2C%20our%20skilled] services has been steadily rising across New Jersey, where residential and commercial projects continue to shape local communities. Whether involving renovations, new builds, or large-scale developments, property owners require professionals who bring both expertise and reliability. Within this landscape, NEA Design and Construction has established itself…
A+ Plumbing & Gas Educates Edmond, OK Homeowners on the Warning Signs of Failing …
A+ Plumbing & Gas helps Edmond, OK residents spot early signs of water heater failure, offering tips to avoid unexpected breakdowns, expensive repairs, and water damage.
Edmond, OK - A+ Plumbing & Gas, a trusted name in plumbing services throughout the Oklahoma City metro area, is educating homeowners in Edmond, OK, about the critical warning signs of failing water heaters. With winter approaching and temperatures beginning to drop, the team at…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
